Pune, India -- (SBWire) -- 10/18/2018 --Market Highlights:

Soft tissue sarcoma is a type of cancer that develops from tissues such as nerves, muscles, fats, blood vessels and deep skin tissues. Generally occuring in the muscles, tissues, and blood vessels that protect, support and surround the organs. Moreover, it is not categorized as tumor, but can be life-threatening if the cancer spreads to other parts of the body. There are around 50 different types of soft tissue sarcoma, such as adult fibrosarcoma, angiosarcoma, clear cell sarcoma, alveolar soft-part sarcoma, kaposi sarcoma, malignant mesenchymoma, rhabdomyosarcoma, and others.

Currently, there are very few products approved for the treatment of soft tissue sarcoma. For instance, in October 2016, U.S. Food and Drug Administration issued an accelerated approval notice for Eli Lilly and Company's drug Lartruvo (Olaratumab) with Doxorubicin to treat certain types soft tissue carcinoma. Some of the drugs used for the treatment of soft tissue sarcoma include trabectedin (yondelis), sunitinib (sutent), sirolimus (rapamune), and doxorubicin (adriamycin), bevacizumab (avastin), and others.

Increase in the incidence and prevalence of different types of cancers, rising cases of soft tissue sarcoma, increasing R&D activities on drugs and other therapies, patent expiry of branded drugs, are some of the factors fuelling the growth of the soft tissue sarcoma market over the forecast period. However, stringent regulatory guidelines, adverse side effects of the treatment, and high cost for the radiotherapy and chemotherapy may hinder the growth of soft tissue sarcoma treatment market over the forecast period.
The methods for diagnosis of soft tissue sarcoma include some physical examination such as X-ray imaging, CT scan, MRI, ultrasound, PET scan and a biopsy. Such examinations in conjugation with other tests are important to plan a suitable treatment method for this condition. The Global Soft Tissue Sarcoma Market is expected to grow at a CAGR of approximately 8.2% during the forecast period 2017-2023.

Get Exclusive Sample Report @ https://www.marketresearchfuture.com/sample_request/5304

Regional Analysis:

Global soft tissue sarcoma consists of regions namely the Americas, Europe, Asia Pacific, and the Middle East and Africa. Americas is expected to lead the global market due to high incidence of cancer and soft tissue sarcoma. According to the American Cancer Society, more than 11,400 new cases of soft tissue sarcoma were diagnosed in the U.S. in 2014. While, Europe is expected to hold the second largest market share in the global market. Market in Asia Pacific region is expected to witness significant growth owing to increasing case of cancer and growing awareness regarding advanced cancer treatments. In addition, increasing healthcare expenditure related to cancer and associated disease is expected to boost the market growth in near future.

Key players of Global Soft Tissue Sarcoma Market:

GlaxoSmithKline plc. (U.K.)
Eli Lilly and Company (U.S.)
Pfizer, Inc. (U.S.)
Bristol-Myers Squibb (U.S.)
F. Hoffmann-La Roche AG (Genentech) (Switzerland)
Johnson & Johnson Services, Inc. (U.S.)
Teva Pharmaceutical Industries Ltd (Israel)
Celgene Corporation (U.S.) and others.

Pharma News:-

Various key players are active in the soft tissue sarcoma treatment market in terms of product launches, research, and development activities. For instance, in 2012, Threshold Pharmaceuticals Inc. signed a global license agreement for Evofosfamide, which is the most advanced first-line drug for soft tissue sarcoma with Merck KGaA. GSK's Votrient (pazopanib) is approved for second-line treatment, and another drug Aldoxorubicin is approved as first-line drug for the treatment of soft tissue sarcoma. Currently, doxorubicin is commonly used for the treatment of soft tissue sarcoma.

Segments:

The soft tissue sarcoma is segmented on the basis of treatment, disease type, distribution channel, and end-users. On the basis of the treatment type, the soft tissue sarcoma treatment market is segmented into targeted therapy, chemotherapy, anti-angiogenesis drugs, radiation therapy. Furthermore, the radiation therapy is subcategorized into internal radiation therapy and external radiation therapy. On the basis of the disease type, soft tissue sarcoma treatment market is segmented into local sarcoma, regional sarcoma, and metastatic sarcoma. On the basis of the distribution channel, soft tissue sarcoma treatment market is segmented into hospital pharmacies, retail pharmacies and other. On the basis of the end user, the global soft tissue sarcoma treatment market has been segmented into hospitals, oncology centers, and long term care centers.

Avail Amazing Discount on Report https://www.marketresearchfuture.com/check-discount/5304

BRIEF TOC:

Chapter 1. Report Prologue

Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations

Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation

LIST OF TABLES
Table 1 Soft Tissue Sarcoma Industry Synopsis, 2017 – 2023
Table 2 Soft Tissue Sarcoma Market Estimates And Forecast, 2017 – 2023, (USD Million)
Table 3 Soft Tissue Sarcoma Market By Region, 2017 – 2023, (USD Million)
Table 4 Soft Tissue Sarcoma Market By Treatment, 2017 – 2023, (USD Million)
Table 5 Soft Tissue Sarcoma Market By Disease Types, 2017 – 2023, (USD Million)
Table 6 Soft Tissue Sarcoma Market By Distribution Channel, 2017 – 2023, (USD Million)
Table 7 Soft Tissue Sarcoma Market By End Users, 2017 – 2023, (USD Million)

LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation For Soft Tissue Sarcoma Market
Figure 3 Segmentation Market Dynamics For Soft Tissue Sarcoma Market
Figure 4 Global Soft Tissue Sarcoma Market Share, By Treatment 2016
Figure 5 Global Soft Tissue Sarcoma Market Share, By Disease Types 2016
Figure 6 Global Soft Tissue Sarcoma Market Share, By Distribution Channel, 2016
Figure 7 Global Soft Tissue Sarcoma Market Share, By End Users, 2016

…TOC CONTINUED

Have a Question Ask to Our Experts @ https://www.marketresearchfuture.com/enquiry/5304

About Market Research Future
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.